Hayakawa I
Nihon Rinsho. 1997 May;55(5):1266-71.
Recently rapid increase in the emergence of multiresistant Gram-positive pathogen such as MRSA, penicillin resistant Streptococcus pneumoniae (PRSP), and vancomycin resistant Enterococcus (VRE). Whether quinolone antibacterial agent (quinolone) come to a promising drug or not for the treatment of these infectious diseases, it depend on an appropriate drug design of quinolones which have good toxicological and pharmacokinetic profile along with excellent antibacterial activities against these Gram-positive pathogens. In this chapter, we examine the possibility by following the history of the advances in quinolone research.
近年来，耐多药革兰氏阳性病原体如耐甲氧西林金黄色葡萄球菌（MRSA）、耐青霉素肺炎链球菌（PRSP）和耐万古霉素肠球菌（VRE）的出现迅速增加。喹诺酮类抗菌剂（喹诺酮）能否成为治疗这些传染病的有前景的药物，取决于喹诺酮类药物的合理设计，这类药物要有良好的毒理学和药代动力学特性，同时对这些革兰氏阳性病原体具有优异的抗菌活性。在本章中，我们通过追溯喹诺酮研究进展的历史来探讨这种可能性。
